Insulet (NASDAQ:PODD) PT Raised to $220.00

Insulet (NASDAQ:PODD) had its target price raised by stock analysts at Barclays from $200.00 to $220.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Barclays‘s price objective would suggest a potential upside of 13.06% from the stock’s previous close.

A number of other brokerages have also recently weighed in on PODD. Canaccord Genuity Group reissued a “buy” rating and set a $234.00 price objective on shares of Insulet in a research report on Tuesday, July 23rd. Redburn Atlantic initiated coverage on Insulet in a report on Thursday, May 30th. They set a “buy” rating and a $235.00 price target for the company. OTR Global restated a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. BTIG Research cut their target price on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, UBS Group increased their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $232.13.

Insulet Trading Up 3.5 %

NASDAQ PODD opened at $194.59 on Monday. The company has a market capitalization of $13.63 billion, a PE ratio of 58.97, a price-to-earnings-growth ratio of 3.53 and a beta of 1.16. Insulet has a 1-year low of $125.82 and a 1-year high of $227.55. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. The firm’s fifty day simple moving average is $196.65 and its 200-day simple moving average is $183.70.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The business had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.38 EPS. As a group, sell-side analysts anticipate that Insulet will post 3.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $199.96, for a total value of $299,940.00. Following the transaction, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Insulet news, Director Timothy J. Scannell sold 7,000 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the sale, the director now owns 35,586 shares of the company’s stock, valued at approximately $6,779,488.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Mark N. Field sold 1,500 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the sale, the senior vice president now owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,931 shares of company stock valued at $2,636,286. 0.47% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insulet

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Profund Advisors LLC bought a new position in shares of Insulet in the 2nd quarter valued at about $220,000. Symmetry Investments LP bought a new position in Insulet in the second quarter valued at approximately $323,000. Sei Investments Co. grew its holdings in Insulet by 148.6% during the 2nd quarter. Sei Investments Co. now owns 29,289 shares of the medical instruments supplier’s stock worth $5,911,000 after acquiring an additional 17,507 shares during the period. Pacer Advisors Inc. grew its holdings in Insulet by 36.3% during the 2nd quarter. Pacer Advisors Inc. now owns 6,506 shares of the medical instruments supplier’s stock worth $1,313,000 after acquiring an additional 1,734 shares during the period. Finally, Beck Bode LLC raised its position in shares of Insulet by 33.6% during the 2nd quarter. Beck Bode LLC now owns 93,187 shares of the medical instruments supplier’s stock valued at $18,805,000 after acquiring an additional 23,426 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.